AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00818155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate SR
Description: desvenlafaxine succinate SR
Study NCT00818155 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00863681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
Study NCT03031496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)
Description: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side.
Study NCT00526448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 2000 mg/day
Study NCT00526448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 1000-1200 mg/day
Study NCT00526448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180 mcg/week
Study NCT00526448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180 mcg/week
Study NCT00526448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta
Description: epoetin beta 450 UI/week
Study NCT04058639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: custom felt relief
Description: Felt is adjusted to the wound by cutting it in different ways and layers once every week
Study NCT04058639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard relief treatment
Description: Felt in the shape of a letter U is put around the wound once every week.
Study NCT01673581 — intervention group
Intervention type: OTHER
Intervention: Survey
Study NCT02805296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light irradiance
Description: Comparison of double vs. single phototherapy
Study NCT00780780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone + Nepafenac
Description: Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
Study NCT00780780 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: triamcinolone intravitreal injection
Description: triamcinolone intravitreal injection
Study NCT02381613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baked beef
Description: A meal based on baked beef
Study NCT02381613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked herring
Description: A meal based on baked herring
Study NCT02381613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pickled herring
Description: A meal based on pickled herring
Study NCT03559504 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane Inhal Soln
Description: Anesthesia will be induced by sevoflurane inhalation only with a tight-fitting facemask and a 4-l airflow of 100% oxygen. Sevoflurane inhalation will be adjusted in all age groups to maintain 1.0 MAC concentration
Study NCT02511041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylglucosamine (GlcNAc)
Description: N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
Study NCT02511041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uridine
Description: Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
Study NCT00527137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
Study NCT00527137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
Study NCT03031496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
Description: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917.
Study NCT02750332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: A single oral dose of Nitisinone 10 mg Tablet will be administered.
Study NCT00947310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard ICD programming
Description: Standard ICD programming
Study NCT00947310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High rate cutoff
Description: Programming of a high rate cutoff
Study NCT00947310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long delay
Description: Programming of a prolonged delay
Study NCT03200561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 2mg/Kg/day for 5 days
Study NCT03200561 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: immunoglobulin
Description: immunoglobulin 2g/Kg for 12 hours
Study NCT03200561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: immunoglobulin
Description: immunoglobulin 2g/Kg for 12 hours
Study NCT04331834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months
Study NCT04331834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months
Study NCT04131712 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Massage
Description: A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
Study NCT02793271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESHAPE
Description: Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
Study NCT02793271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIME/mhGAP
Description: Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions.
Study NCT02793271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIME/mhGAP
Description: Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions.
Study NCT02653612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC17 imaging contrast agent
Description: This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Study NCT04131712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
Study NCT02073240 — intervention group
Intervention type: BEHAVIORAL
Intervention: Enhanced TB IC Package
Description: Facilities randomized to the intervention group will receive:~1. Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~2. Audits and Feedback of performance~3. A TB IC collaborative membership~4. A standardized unit-level daily checklist of critical IC activities
Study NCT00288418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Central Venous Catheter
Description: 7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
Study NCT02257476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
Study NCT02257476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
Study NCT00288418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central Venous Catheter
Description: 7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
Study NCT04474561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reduced sulfur diet
Description: A reduced sulfur diet includes reducing foods, food additives (e.g., carrageenan) and beverages high in sulfate/sulfur, limiting sulfur containing supplements, and consuming omega-3 fatty acid supplements to potentially help control overgrowth of sulfur-reducing bacteria in the colon. Omega-3 fatty acid intake for cardiovascular disease prevention should be around 500 mg/d23. After dietary assessment if patients are not meeting their required daily intake of 500 mg/d of Omega-3, the RD will recommend increased fish consumption to 200 g per week or 1 g/d of an Omega-3 supplement. This will ensure the daily recommended intake of 500 mg/d is being met to reduce the chances of a deficiency; however, a therapeutic dose for UC will not be recommended (i.e., > 4 g/d18).
Study NCT04300712 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires at the start and end of the school year
Description: Interventions will be proposed to children identified in a worrisome situation. The Strengths and Difficulties. Questionnaire will be used by teachers to score these situations. The recognition process of mental health problem and need continue with responses. Responses are supporting a graduated response process in school and facilitating external support when needed (mental health services, community supports). Early intervention is one of all responses, which involve caregivers. Responses to worrisome situations aim to improve schooling conditions, to acknowledge mental health problems or condition and the health services need for children. To evaluate the intervention, the impact supplement of SDQ and the follow-up questions will be used by the teachers and the parents of children who benefit of the intervention. The interventions will be experimented during year 2020-21. Children might benefit of them from several weeks to one year, according to their need.
Study NCT02363387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives for Viral Suppression
Description: Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
Study NCT02363387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard HIV Medical Care
Description: The best HIV medical care available in each participant's medical clinic.
Study NCT02363387 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard HIV Medical Care
Description: The best HIV medical care available in each participant's medical clinic.
Study NCT03498313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol + Placebo
Description: .1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
Study NCT03498313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone + Placebo
Description: 100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
Study NCT03498313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
Study NCT05748132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined conventional and pulsed RF
Description: 1. the classic Hartle technique is used to reach the Gasserian ganglion~2. Sensory stimulation with the RF equipment is conducted and parathesia of the affected branch is achieved at 0.1-0.2 V (50 Hz), keeping in mind that the mandibular part of the Gasserian ganglion is ventrolateral and the ophthalmic rootlets are postrolateral. Motor pre-stimulation (2 Hz) is achieved with masseter contraction at 0.1-0.3 V .~3. After sensory and motor stimulation, RF therapy is conducted by use of the RF generator , in the sequence:~   * Conventional RF 1st lesion at 60 °C for 60 s then 2nd lesion at 65°C for 60 seconds then 3rd lesion at 70°C for 60 seconds~  * Finally, PRF is applied for 360 second repeated at 45 V, with a pulse width of 10 ms and a pulse frequency of 4 Hz. The cut-off needle tip temperature is set at 42 °C.~4. Before withdrawal of needle 1 cc xylocaine 1% + 0.5 cc dexamethasone 4mg to be given
Study NCT02953483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red blood cells
Description: Packed red blood cells to final hematocrit of 14%
Study NCT00186342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablative allogeneic hematopoietic cell transplantation
Study NCT01737307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: Fluoride Varnish (NaF 5%)
Study NCT01737307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Hygiene
Description: Oral hygiene followed.
Study NCT01737307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Description: CPP-ACP paste was applied by patient, once daily.
Study NCT04378686 — intervention group
Intervention type: OTHER
Intervention: dialysis
Description: treatment with dialysis. This can be hemodialysis, hemodiafiltration, peritoneal dialysis
Study NCT02288702 — intervention group
Intervention type: DEVICE
Intervention: monitoring BIS in both groups
Description: We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
Study NCT01653457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~* 1st week: 5 mg daily~* 2nd week: 10 mg daily~* 3rd week: 15 mg daily~* From 4th week up to 24th week: 20 mg daily
Study NCT01653457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
Study NCT04413344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: TW-012R: Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
Study NCT04413344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo: Identical tablets which contain no active ingredient
Study NCT03685097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System with the QPlus Cartridge
Description: Point-of-care viscoelastic testing
Study NCT02762448 — intervention group
Intervention type: DRUG
Intervention: Daclatasvir+ Asunaprevir
Description: HCV clearance and complete regression of NHL by ASV+ DCV
Study NCT03941340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14]-AST2818
Description: Volunteer will receive a single oral dose of 80 mg /100 u Ci \[14C\]-AST2818 as a solution on Day 1
Study NCT04398940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139
Description: TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
Study NCT01290419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Particle Vaccine
Description: Dose 1 + adjuvant / dose; Day 0 and Day 30
Study NCT01290419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Particle Vaccine
Description: Dose 2 + adjuvant / dose; Day 0 and Day 30
Study NCT01290419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Particle Vaccine
Description: Dose 3 + adjuvant / dose; Day 0 and Day 30
Study NCT01290419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Particle Vaccine
Description: Dose 3 / dose; Day 0 and Day 30
Study NCT01290419 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; Day 0 and Day 30
Study NCT01290419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Particle Vaccine
Description: Dose 4 / dose; Day 0 and Day 30
Study NCT01290419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Particle Vaccine
Description: Dose 4 + adjuvant / dose; Day 0 and Day 30
Study NCT03077893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Provant Therapy System
Description: Treatment with active Provant Therapy System
Study NCT03077893 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive (sham) Provant Therapy System
Description: Treatment with Inactive (sham) Provant Therapy System
Study NCT02478515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intraviteal injection of 0.5mg ranibizumab
Study NCT03062215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Depression
Description: Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
Study NCT03036371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: 6 week at-home aerobic exercise protocol
Study NCT03175614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
Study NCT03175614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Lifestyle counseling
Description: Conseling on physical activity and nutrition (intervention)
Study NCT03175614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control: Lifestyle counseling
Description: Conseling on physical activity and nutrition (intervention)
Study NCT02410863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150 mg twice daily
Study NCT02410863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2 mg daily